FIGURE 1.
Disease etiology, treatment, and outcomes of patients with ALI
| Study | Study group value | Control group value | Cut-off value | AUC/ROC analysis | Sensitivity (%) | Specificity (%) | Outcome |
|---|---|---|---|---|---|---|---|
| ALI | |||||||
| Taşoğlu et al.27 | 9.7 | 6.1 | 5.2 | 0.7 | 63% | 63% | Amputation |
| Coelho et al.28 | 8.8 | 3.6 | 5.4 | 0.860 | 90.5% | 73.6% | Death or major amputation at 30 days |
| Taurino et al.29 | – | – | 5 | 0,823 | – | – | Amputation at 30 days |
| – | – | 5 | 0.776 | – | – | Mortality at 30 days | |
| Pasqui et al.30 | 8.9 | 6.5 | 6.66 | 0.712 | 77.8% | 65.3% | Amputation at 26.9 ± 22.1 months |
| 8.08 | 5.6 | 5.57 | 0.639 | 62.3% | 56.04% | Mortality at 26.9 ± 22.1 months | |
| Arbănași et al.31 | 5.78 | 2.61 | 4.23 | 0.829 | 70.2% | 83% | Major amputation at 30 days |
| CLTI | |||||||
| Spark et al.32 | – | – | 5.25 | 0.690 | 69% | 71% | Mortality at 8.7 months (3.1–16 months) |
| Chan et al.33 | – | – | 5.25 | – | – | – | Mortality at 12 months |
| Gonzalez-Fajardo et al.34 | – | – | 5 | 0.64 | 32% | 87.5% | Amputation-free survival at 31 months |
| Erturk et al.35 | – | – | 3 | – | – | – | Cardiovascular death at 20 months (12–27 months) |
| Taşoğlu et al.36 | 3.8 | 2.4 | 3.2 | 0.71 | – | – | Major amputation at 46 months |
| Su et al.37 | – | – | 8 | – | 62% | 82.1% | Mortality at 12 months |
| Russu et al.38 | 6.40 | 2.21 | 3.95 | 0.821 | 82.6% | 89.9% | Primary patency at 12 months |
Clinical cases and surgical procedures for ALI
| Study | Cause | Location | Treatment | Complication | ||||||
|---|---|---|---|---|---|---|---|---|---|---|
| Embolic, n (%) | Thrombotic, n (%) | Aorto-iliac, n (%) | Femoral-popliteal axis, n (%) | Below the knee artery, n (%) | Embolectomy, n (%) | Bypass, n (%) | Other, n (%) | Amputation, n (%) | Mortality, n (%) | |
| Taşoğlu et al.27 | 224 (92%) | 21 (8%) | 44 (18%) | 189 (78%) | – | 224 (92%) | 21 (8%) | – | 36 (14.69%) | 25 (10%) |
| Coelho et al.28 | 157 (45.5%) | 188 (54.5%) | 60 (17.4%) | 261 (75.7%) | 24 (7%) | 280 (81.2%) | 35 (10.1%) | 30 (8.7%) | 84 (24.34%) | – |
| Taurino et al.29 | 73 (41.3%) | 104 (58.7%) | – | – | – | 95 (53.7%) | 9 (5.1%) | 73 (41.2%) | 23 (12.9%) | 29 (16.4%) |
| Pasqui et al.30 | 67 (39.9%) | 121 (60.1%) | 19 (11.3%) | 138 (82.1%) | 11 (6.5%) | – | – | – | 18 (10.7%) | 77 (45.8%) |
| Arbănași et al.31 | – | – | – | – | – | 118 (72.39%) | 38 (23.31%) | 7 (4.29%) | 57 (27.14%) | 47 (22.38%) |
The general characteristics of the studies included in the review
| Study | Year | Country | No. of patients | Mean age (years) | Male sex, n (%) | Hypertension, n (%) | Ischemic heart disease, n (%) | Diabetes, n (%) | Active smoking, n (%) |
|---|---|---|---|---|---|---|---|---|---|
| ALI | |||||||||
| Taşoğlu et al.27 | 2013 | Turkey | 245 | 66.04 | 152 (62%) | 144 (59%) | – | 60 (24%) | 170 (70%) |
| Coelho et al.28 | 2021 | Portugal | 345 | 73 | 188 (54.5%) | 277 (83.5%) | 157 (45.5%) | 92 (27.5%) | 136 (39.4%) |
| Taurino et al.29 | 2021 | Italy | 177 | 78.9 | 115 (65%) | 145 (81.9%) | – | 70 (39.5%) | – |
| Pasqui et al.30 | 2021 | Italy | 168 | 77.8 | 109 (64.9%) | 128 (76.1%) | 45 (26.7%) | 54 (32.1%) | 18 (10.7%) |
| Arbănași et al.31 | 2022 | Romania | 210 | 69.56 | 153 (72.86%) | 175 (83.33%) | 169 (80.48%) | 111 (52.86%) | 134 (63.81%) |
| CLTI | |||||||||
| Spark et al.32 | 2010 | UK | 149 | 72 | – | 83 (55.7%) | – | 44 (29.53%) | 103 (69.12%) |
| Chan et al.33 | 2014 | Australia | 97 | 81 | 50 (64.9%) | 42 (54.6%) | 49 (63.6%) | 46 (59.7%) | – |
| Gonzalez-Fajardo et al.34 | 2014 | Spain | 561 | 74 | 465 (83%) | 354 (63.10%) | 131 (23.35%) | 258 (45.98%) | 362 (64.52%) |
| Erturk et al.35 | 2014 | Turkey | 508 | 64 | 413 (81.3%) | 311 (61.22%) | 207 (40.74%) | 213 (41.92%) | 266 (52.36%) |
| Taşoğlu et al.36 | 2014 | Turkey | 104 | 69 | 86 (82.7%) | 46 (44.2%) | – | 39 (37.5%) | 74 (71.2%) |
| Su et al.37 | 2021 | Taiwan | 195 | 74 | 102 (52.3%) | 129 (66.15%) | 75 (38.46%) | 134 (68.71%) | 46 (23.58%) |
| Russu et al.38 | 2022 | Romania | 224 | 69.72 | 166 (74.11%) | 186 (83.04%) | 181 (80.8%) | 110 (49.11%) | 141 (62.95%) |